Halifax, Nova Scotia; June 14, 2012 – Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX-V: IMV), a clinical stage vaccine company developing the patented DepoVax™ vaccine adjuvanting platform and product candidates for cancer therapy and infectious diseases, today announced that the 2012 Warwick Kimmins Science Scholarship in the amount of $1,000 has been awarded to Alicia Donovan. Alicia is graduating from St. Malachy’s Memorial High School and will attend the University of New Brunswick in September.
“Through her essay Alicia demonstrated both a solid foundation of scientific understanding and the capacity to conceive of novel approaches to problem solving. Her personal connection to the research she intends to pursue will only add to the drive and dedication she brings to the laboratory,” said Dr. Ryan D’Arcy, a neuroscientist at the National Research Council and the judge for the Warwick Kimmins Science Scholarship.
Alicia’s interest in scientific research focused on next generation vaccines is directly inspired by her experiences in witnessing her father’s battles against several health complications resulting from his previous battle with Non-Hodgkin’s Lymphoma. Her goal is to spearhead research designed to develop a novel vaccine with mutating antigens which could benefit individuals stricken with weakened immune systems.
“Alicia demonstrated herself to be an excellent choice for this scholarship based on her outstanding academic achievement, leadership in her school and community and extensive volunteer activities,” continued Dr. D’Arcy. “We are pleased to offer her this scholarship and wish her great success in pursuit of her Bachelor of Science & Art degree, majoring in biology at the University of New Brunswick.”
The scholarship is in memory of Dr. Warwick Kimmins, co-founder of Immunovaccine Inc. Dr. Kimmins was the former Dean of the Faculty of Science at Dalhousie University and was instrumental in advancing Immunovaccine to its current stage of development.
Immunovaccine Inc. applies its novel vaccine delivery platform to the development of vaccines for cancer therapy and infectious diseases. The Company’s DepoVax™ platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses. Immunovaccine has advanced its platform technology and proprietary cancer vaccine into Phase I human clinical trials and has demonstrated both safety and immunogenicity potential. The Company is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based vaccines through multiple development collaborations. In addition to the Company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has several key partnerships in the animal health sector including an agreement with Pfizer Animal Health, which has licensed the Company’s delivery technology platform to develop vaccines for livestock. Connect at www.imvaccine.com.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Kimberly Stephens, Immunovaccine Inc.
T: (902) 492-1819 E: email@example.com
Tim Brons, Vida Communication (media)
T: (415) 675-7402 E : firstname.lastname@example.org
Stephanie Diaz, Vida Communication (investors)
T: (415) 675-7401 E : email@example.com
Nadine Desruisseaux, Capital Ideas Investor Relations (Investors – Canada)
T: (647) 202-5292 E: nadine@capitalideasIR.com